Your Health. Your Family. Your Choice.
|History of Changes from the VAERS Wayback Machine|
First Appeared on 12/7/2010
|Vaccination / Manufacturer||Lot / Dose||Site / Route|
|HPV4: HPV (GARDASIL) / MERCK & CO. INC.||AHPVA062AA / -||UN / IM|
Administered by: Other Purchased by: Other
Symptoms: Dizziness, Labyrinthitis, Activities of daily living impaired
Life Threatening? No
Permanent Disability? Yes
ER or Doctor Visit? No
Current Illness: Unknown
Preexisting Conditions: Viral Infection; Nil medical history/Nil allergies. Patient asked prior to vaccination regarding current or recent illness and replied nil.
Diagnostic Lab Data: UNK
CDC 'Split Type': B0681392A
Write-up:This case was reported by the MHRA (GB-MHRA-ADR 20725824) and described the occurrence of dizziness in a 12-year-old female subject who was vaccinated with CERVARIX. The subject''s concurrent medical history included viral infection. It was reported that prior to vaccination the subject had no recent illnesses and no allergies. On 24 September 2010 the subject received a dose of CERVARIX (.5 ml, intramuscular). Approximately 1 day later, on 25 September 2010, after vaccination with CERVARIX, the subject experienced persistent dizziness and labyrinthitis. The regulatory authority reported that the events were disabling. The subject was prescribed with prochlorperazine for persistent dizziness. The event labyrinthitis was diagnosed by the paediatric consultant as secondary to the vaccine given, whilst patient had a viral cold. At the time of reporting the events were unresolved. MHRA Verbatim Text: Persistent dizziness - prescribed prochlorperazine. Labyrinthitis diagnosed by paediatric consultant as secondary to vaccine given whilst patient had a viral cold. Patient seen by GP, local A&E department, and referred for investigation at a hospital with subsequent diagnosis. Patient unable to return to school at present.
Copyright © 2017 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166